Cardio3Biosciences acquires CorQuest Medical

Cardio3BioSciences has acquired US-based CorQuest Medical, which specializes in the development of innovative devices and technologies for cardiac surgery. Specifically, CorQuest's novel heart access technology comprises a number of instruments which allows for quick, user friendly and easy trans-thoracic access to the heart, directly into the left atrium, ensuring a minimally invasive approach to deliver numerous existing therapeutic devices. This unique heart access platform could receive CE marking by end 2016. When CE-marked, the insertion of the heart access sheath into a patient's left atrium will allow the deployment of catheters or other necessary instruments for use in the treatment of various indications such as mitral valve occlusion defects.